ISBN: 9783764371999 - aromatase inhibitors (mdt - milestones in drug therapy) (4 Ergebnisse)

- Hardcover
Anbieter: Romtrade Corp., STERLING HEIGHTS, MI, USARomtrade Corp.
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Neu
EUR 105,03
Versand gratisVersand innerhalb von USAAnzahl: 1 verfügbar
Zustand: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.

- Hardcover
Anbieter: Majestic Books, Hounslow, Vereinigtes KönigreichMajestic Books
Verkäufer/-in kontaktierenVerkäufer/-in mit 4 SternenZustand: Gebraucht
EUR 145,55
EUR 7,76 VersandVersand von Vereinigtes Königreich nach USAAnzahl: 1 verfügbar
Zustand: Used. pp. 182.

- Hardcover
Anbieter: Biblios, frankfurt am main, HESSE, DeutschlandBiblios
Verkäufer/-in kontaktierenVerkäufer/-in mit 4 SternenZustand: Gebraucht
EUR 146,13
EUR 9,95 VersandVersand von Deutschland nach USAAnzahl: 1 verfügbar
Zustand: Used. pp. 182.

- Hardcover
Anbieter: CSG Onlinebuch GMBH, Darmstadt, DeutschlandCSG Onlinebuch GMBH
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Gebraucht - Sehr gut
EUR 62,48
EUR 95,00 VersandVersand von Deutschland nach USAAnzahl: 1 verfügbar
hard bound. Zustand: Sehr gut. Gebraucht - Sehr gut about this book: Many breast tumours are dependent upon oestrogen for their development and continued growth. Over the last 25 years hormone therapy has progressed from the irreversible destruction of endocrine glands to the use of drugs that reversibly suppress oestrogen synthesis or action. The inhibition of oestrogen synthesis is most readily achieved by inhibiting the final step in the pathway of oestrogen biosynthesis, the reaction which transforms androgens into oestrogens by creating an aromatic ring in the steroid molecule (hence the enzyme's trivial name, aromatase). Whereas the first aromatase inhibitors to be used therapeutically could be shown to produce drug-induced inhibition of the enzyme and therapeutic benefits in patients with breast cancer, they were not particularly potent and lacked specificity. However, second-generation drugs were developed and most recently third-generation inhibitors have evolved which possess remarkable specificity and potency. Initial results from clinical trials suggest that these agents will become the cornerstones of future endocrine therapy. Written for: Scientific libraries, pharmaceutical industry, researchers and clinicians; postgraduate students.…